Résumés Ballut, Christèle; Burgess, Andrea; Collis, John ...
Le Pâtural Clermont-Ferrand Puy-de-Dôme,
03/2017
Journal Article
Résumé Les Arvernes sont, parmi les peuples de la Gaule, les plus fréquemment et les plus anciennement cités par les auteurs antiques. En dehors des trois oppida (Corent, Gondole et Gergovie) du sud ...de la Limagne, la connaissance du territoire arverne était, jusqu’à il y quelques années, très fragmentaire. Les nombreuses prospections archéologiques menées en Limagne ainsi que le développement de l’archéologie préventive dans le grand bassin clermontois permettent, depuis peu, de restituer une...
Bibliographie Ballut, Christèle; Burgess, Andrea; Collis, John ...
Le Pâtural Clermont-Ferrand Puy-de-Dôme,
03/2017
Journal Article
Alfonso à paraître : ALFONSO (G.). — Le site de Gerzat à Rochefort (Puy-de-Dôme). In : MENNESSIER-JOUANNET (C.). — Les âges du Fer en Auvergne : 27e colloque international de l’AFEAF, ...Clermont-Ferrand, mai-juin 2003. Lattes : UMR 154, CNRS, à paraître. Alfonso, Blaizot 2004 : ALFONSO (G.), BLAIZOT (F.). — La villa gallo-romaine de Champ Madame à Beaumont (Puy-de-Dôme) : habitat et ensemble funéraire de nourrissons. Lyon : ALPARA, 2004. 282 p. (DARA ; 27). Amar, Liou 1984 : AMAR (G.), LIOU (B...
Abréviations Ballut, Christèle; Burgess, Andrea; Collis, John ...
Le Pâtural Clermont-Ferrand Puy-de-Dôme,
03/2017
Journal Article
ABELL : Association bourguignonne d’études linguistiques et littérairesADEL : Association pour la défense et l’étude du canton de LevrouxAFEAF : Association française pour l’étude de l’âge du ...ferALPARA : Association de liaison pour le patrimoine et l’archéologie en Rhône-Alpes et en AuvergneAfan : Association pour les fouilles archéologiques nationalesAPDCA : Association pour la promotion et la diffusion des connaissances archéologiquesARAFA : Association pour la recherche sur l’âge du Fer en...
Pages liminaires Ballut, Christèle; Burgess, Andrea; Collis, John ...
Le Pâtural Clermont-Ferrand Puy-de-Dôme,
03/2017
Journal Article
Remerciements Les auteurs tiennent à adresser leurs plus vifs remerciements à Élise Boucharlat, Bernadette Fizelier-Sauget, Louis Blanchard ainsi qu’à la cellule éditoriale de l’ALPARA, pour leur ...fort investissement dans ce projet de publication. Principaux contributeurs CB : Christèle Ballut ; Centre national de la recherche scientifique, GÉOLAB, UMR 6042.JC : John Collis ; Département d’archéologie, Université de Sheffield.YD : Yann Deberge ; Association pour la recherche sur l’âge du Fer e...
For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic ...effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic ‘fashions’, and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic ...effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic ‘fashions’, and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
Within the last three years, advances in the fields of cardiac surgery and immunology have established the value of cardiac transplantation for patients with irreversible myopathic disease. ...Long-distance donor procurement has increased the availability of the donor pool and made possible a more critical selection of donor hearts. The development of antithymocyte globulin and the concept of individual immune monitoring has decreased the incidence of acute rejection and the dosage of prednisone and azathioprine necessary to achieve optimal graft protection. These advances are reflected in the survival statistics. Since 1977, the three-month mortality rate has decreased to 40%, as compared to 77% from 1968 to 1976. Ptatients who are discharged from the hospital are currently demonstrating an 88% one-year survival rate and are functional class I-II status. We conclude that in properly selected patients, cardiac transplantation is a viable option for end-stage cardiomyopathic disease.
Interview with a Nobel Laureate Burtch, Robert L.; Laureate, Nobel; Hermann, Abbie ...
Science and children,
11/1990, Letnik:
28, Številka:
3
Journal Article
PDF
